Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV

被引:120
作者
Frank, DW
Vallis, A
Wiener-Kronish, JP
Roy-Burman, A
Spack, EG
Mullaney, BP
Megdoud, M
Marks, JD
Fritz, R
Sawa, T
机构
[1] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, Anesthesia Res Lab, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Pediat, Div Crit Care Med, San Francisco, CA 94143 USA
[5] Inter Mune, Brisbane, CA USA
[6] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA
关键词
D O I
10.1086/341069
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pseudomonas aeruginosa is a gram-negative pathogen causing life-threatening infections. Lung injury and the development of sepsis depend largely on the expression of type III secretion system (TTSS) virulence. TTSS functions as a molecular syringe to deliver toxins directly to the cytosol of cells, inhibit innate immune mechanisms, and prevent bacterial clearance. Polyclonal antibodies that bind to PcrV of P. aeruginosa inhibit the delivery of type III toxins and enhance the clearance of bacteria during acute lung infections. PcrV is a homologue of LcrV, a protective antigen in the Yersinia TTSS and an integral component of TTSS. In this study, a murine monoclonal antibody (MAb) to PcrV was generated: MAb 166, which is protective against P. aeruginosa when coinstilled with the bacterial inoculum or intraperitoneally transferred to mice. Fab fragments from MAb 166 prevent sepsis and death. The epitope bound by MAb 166 was mapped to the carboxyl-terminus of PcrV.
引用
收藏
页码:64 / 73
页数:10
相关论文
共 33 条
  • [1] Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis
    Anderson, GW
    Leary, SEC
    Williamson, ED
    Titball, RW
    Welkos, SL
    Worsham, PL
    Friedlander, AM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (11) : 4580 - 4585
  • [2] BURROWS TW, 1956, BRIT J EXP PATHOL, V37, P481
  • [3] BURROWS TW, 1958, BRIT J EXP PATHOL, V39, P278
  • [4] Antibody-based therapies for emerging infectious diseases
    Casadevall, A
    [J]. EMERGING INFECTIOUS DISEASES, 1996, 2 (03) : 200 - 208
  • [5] SERUM THERAPY REVISITED - ANIMAL-MODELS OF INFECTION AND DEVELOPMENT OF PASSIVE ANTIBODY THERAPY
    CASADEVALL, A
    SCHARFF, MD
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (08) : 1695 - 1702
  • [6] ExoT of cytotoxic Pseudomonas aeruginosa prevents uptake by corneal epithelial cells
    Cowell, BA
    Chen, DY
    Frank, DW
    Vallis, AJ
    Fleiszig, SMJ
    [J]. INFECTION AND IMMUNITY, 2000, 68 (01) : 403 - 406
  • [7] Craven D E, 1996, Semin Respir Infect, V11, P32
  • [8] Virulence role of V antigen of Yersinia pestis at the bacterial surface
    Fields, KA
    Nilles, ML
    Cowan, C
    Straley, SC
    [J]. INFECTION AND IMMUNITY, 1999, 67 (10) : 5395 - 5408
  • [9] ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury
    FinckBarbancon, V
    Goranson, J
    Zhu, L
    Sawa, T
    WienerKronish, JP
    Fleiszig, SMJ
    Wu, C
    MendeMueller, L
    Frank, DW
    [J]. MOLECULAR MICROBIOLOGY, 1997, 25 (03) : 547 - 557
  • [10] The exoenzyme S regulon of Pseudomonas aeruginosa
    Frank, DW
    [J]. MOLECULAR MICROBIOLOGY, 1997, 26 (04) : 621 - 629